IDGGW (Interpace Biosciences) Interest Expense : $-0.66 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Interpace Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Interpace Biosciences's interest expense for the three months ended in Dec. 2024 was $ -0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.66 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Interpace Biosciences's Operating Income for the three months ended in Dec. 2024 was $ 3.07 Mil. Interpace Biosciences's Interest Expense for the three months ended in Dec. 2024 was $ -0.11 Mil. Interpace Biosciences's Interest Coverage for the quarter that ended in Dec. 2024 was 27.68. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interpace Biosciences Interest Expense Historical Data

The historical data trend for Interpace Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Interest Expense Chart

Interpace Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.55

-1.04

-1.01

-0.66

Interpace Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.23	-0.22	-0.19	-0.15	-0.11

Interpace Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.66 Mil.

Interpace Biosciences (OTCPK:IDGGW) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interpace Biosciences's Interest Expense for the three months ended in Dec. 2024 was $-0.11 Mil. Its Operating Income for the three months ended in Dec. 2024 was $3.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $1.18 Mil.

Interpace Biosciences's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	3.072	/	-0.111
	=	27.68

The higher the ratio, the stronger the company's financial strength is.

Interpace Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDGGW) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

IDXG:USA PF42:Germany

Address

2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.